MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 881 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
p38-α MAPK-IN-5
CAS:<p>p38-α MAPK-IN-5: potent p38α inhibitor, IC50s: 0.1 nM (α), 0.2 nM (β), 944 nM (γ), 4100 nM (δ); anti-inflammatory, promising for asthma/COPD research.</p>Fórmula:C37H49N11O2Cor e Forma:SolidPeso molecular:679.86pan-Raf/RTK inhibitor 1
CAS:<p>Pan-Raf/RTK inhibitor 1 (compound I-16) is a potent pan-Raf inhibitor with IC50 values of 3.49 nM (BRafV600E), 8.86 nM (ARaf), 5.78 nM (BRafWT), and 1.65 nM (CRaf). It exhibits antiproliferative activity against various cancer cell lines and can be utilized in cancer research.</p>Fórmula:C29H28F3N7O3Cor e Forma:SolidPeso molecular:579.573KRAS inhibitor-27
CAS:<p>KRAS inhibitor-27 (Compound 15h) is a KRAS inhibitor that effectively targets KRAS G12D/G12V mutated cells (AsPC-1 and SW620) and wild-type KRAS cells (HT-29), with IC50 values of 378 nM, 0.6 nM, and 3230 nM, respectively. It reduces ERK phosphorylation, with IC50 values of 0.6 nM and 1 nM in AsPC-1 and SW620 cells, respectively, and decreases DUSP4 expression, thereby inhibiting the MAPK signaling pathway.</p>Fórmula:C31H28ClF3N6O3SCor e Forma:SolidPeso molecular:657.106p38α-MK2-IN-1
CAS:<p>p38α-MK2-IN-1 (Compound 36) is an inhibitor of the p38α-MK2 complex, with an IC50 of 5 nM. This compound exhibits significant anti-inflammatory properties and has the ability to aid in joint repair.</p>Fórmula:C27H26F3N5O3Cor e Forma:SolidPeso molecular:525.522KU004
CAS:<p>KU004, a potent dual EGFR/HER2 inhibitor, exhibits anticancer properties. It inhibits the proliferation of human breast cancer SKBR3 cells by inducing G1 phase arrest. KU004 blocks the activation of HER2, EGFR, and the downstream Akt and Erk pathways, primarily inducing apoptosis (Apoptosis) through the extrinsic pathway. Additionally, KU004 is a novel quinazoline derivative.</p>Fórmula:C29H27ClFN4O2PCor e Forma:SolidPeso molecular:548.98KRAS inhibitor-8
CAS:<p>KRAS inhibitor-8 is a potent KRAS G12C inhibitor.</p>Fórmula:C26H24ClF4N5O3Pureza:98%Cor e Forma:SolidPeso molecular:565.95RGT-018
CAS:<p>RGT-018 is a potent oral SOS1 inhibitor with antitumor properties. It exerts its anticancer activity by inhibiting KRAS activation, thereby hindering cancer cell proliferation.</p>Fórmula:C27H24F3N7O2Cor e Forma:SolidPeso molecular:535.52KRAS inhibitor-31
CAS:<p>KRAS inhibitor-31 (compound 33), a potent agent targeting KRAS, exhibits K D (SPR) values of 0.019 nM for KRas G12D, 0.019 nM for KRas G12C, and 0.096 nM for KRas G12V, illustrating its efficacy across these variants.</p>Fórmula:C33H30F3N5O4Cor e Forma:SolidPeso molecular:617.62PF-03715455
CAS:PF-03715455 is a potent p38 MAPK inhibitor, reducing TNFα in blood (IC50=1.7 nM) with selectivity for p38α, and may treat COPD.Fórmula:C35H34ClN7O3S2Pureza:98%Cor e Forma:SolidPeso molecular:700.27PS-166276
CAS:<p>PS-166276 is a potent p38 inhibitor with low cytotoxicity. It exhibits an IC50 value of 28 nM against p38 kinase and an IC50 of 170 nM in the THP-1 TNFα assay.</p>Fórmula:C20H30N8OCor e Forma:SolidPeso molecular:398.51Luvometinib
CAS:<p>Luvometinib is an inhibitor of the mitogen-activated protein kinase (MEK) with antitumor activity.</p>Fórmula:C26H22F2IN5O4SCor e Forma:SolidPeso molecular:665.45KRas G12C inhibitor 2
CAS:<p>KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.</p>Fórmula:C32H37N7O3Pureza:98%Cor e Forma:SolidPeso molecular:567.68FMK-MEA
CAS:<p>FMK-MEA is a potent and selective p90 Ribosomal S6 Kinase (RSK) inhibitor.</p>Fórmula:C21H26FN5O2Pureza:98%Cor e Forma:SolidPeso molecular:399.46KRAS G12D inhibitor 26
CAS:<p>KRAS G12D inhibitor 26 (Compound 64B) is an inhibitor of KRAS G12D with an IC50 ≤ 100 nM.</p>Fórmula:C35H44ClFN8O2Pureza:99.93%Cor e Forma:SolidPeso molecular:663.23SR-302
CAS:<p>SR-302 is a potent and selective inhibitor of DDR/p38, with IC50 values of 0.125 μM for p38α, 0.023 μM for DDR1, and 0.018 μM for DDR2. It is utilized in research related to fibrotic diseases, such as kidney and lung fibrosis, atherosclerosis, and various types of cancer.</p>Fórmula:C32H42N6O5SCor e Forma:SolidPeso molecular:622.778(R)-STU104-d6
CAS:<p>(R)-STU104-d6 is a deuterium-labeled variant of (R)-STU104. This compound acts as a potent and orally active inhibitor of the interaction between TAK1 and MKK3 proteins, exhibiting IC50 values of 0.58 μM for TNF-α and 4.0 μM for MKK3 phosphorylation. By binding to MKK3, (R)-STU104 hinders TAK1's ability to phosphorylate MKK3, thereby disrupting the TAK1/MKK3/p38/MnK1/MK2/elF4E signaling pathway. It is utilized in research related to ulcerative colitis.</p>Fórmula:C18H182D6O4Cor e Forma:SolidPeso molecular:304.37MRTX-EX185
<p>MRTX-EX185 inhibits GDP-KRAS/G12D; IC50=90 nM on G12D. It also binds GDP-HRAS.</p>Fórmula:C33H33FN6O2Cor e Forma:SolidPeso molecular:564.65KRASG12C IN-15
CAS:<p>KRASG12C IN-15 (Compound 21) is an orally active KRASG12C inhibitor that effectively blocks SOS1-mediated GDP/GTP exchange with an IC50 of 19 nM. It inhibits ERK phosphorylation with an IC50 of 0.051 μM and reduces the viability of KRASG12C mutant MIA PaCa-2 cells with an IC50 of 0.023 μM. Additionally, KRASG12C IN-15 demonstrates antitumor activity in a MIA PaCa-2 xenograft mouse model.</p>Fórmula:C31H32FN3O2Cor e Forma:SolidPeso molecular:497.603KRAS G12C inhibitor 37
CAS:<p>KRAS G12C inhibitor 37 targets a key signaling protein, showing promise for cancer research involving KRAS G12C.</p>Fórmula:C35H39F3N8O2Cor e Forma:SolidPeso molecular:660.73(rel)-AR234960
CAS:(rel)-AR234960 is an active relative configuration of AR234960. AR234960 is a non-peptide agonist of MAS.Fórmula:C27H30FN5O5SCor e Forma:SolidPeso molecular:555.63
